Skip to main content
SpringerLink
Log in

Atrial Fibrillation: Practical Approaches

  • Chapter
Cardiology for the primary care Physician

  • 106 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. Kannel WB, Wolf PA, Benjamin EJ, et al.: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol1998, 82(suppl):2–9.

    Article  Google Scholar 

  2. Iacovino JR: Mortality of atrial fibrillation in a population selected to be free of major cardiovascular impairments. Jlnsur Med 1999, 31: 8–12.

    CAS  Google Scholar 

  3. Furberg CD, Psaty BM, Manolio TA, et al.: Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol1994, 74: 236–241.

    Article  PubMed  CAS  Google Scholar 

  4. Wolf PA, Abbot RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22: 983–988.

    Article  PubMed  CAS  Google Scholar 

  5. Feinberg WM, Blackshear JL, Laupacis A, et al.: Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995, 155: 469–473.

    Article  PubMed  CAS  Google Scholar 

  6. Levy S: Epidemiology and classification of atrial fibrillation./ Cardiovasc Electrophysiol1998, 9(suppl):78–82.

    Google Scholar 

  7. Ryder KM, Benjamin EJ: Epidemiology and significance of atrial fibrillation. Am J Cardiol1999, 84(suppl A):131–138.

    Google Scholar 

  8. Wolf PA, et al.: Impact of atrial fibrillation on mortality, stroke, and medical costs see comments. Arch Intern Med 1998, 158: 229–234.

    Article  PubMed  CAS  Google Scholar 

  9. Levy S, Maarek M, Coumel P, et al.: Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999, 99: 3028–3035.

    Article  PubMed  CAS  Google Scholar 

  10. Lowenstein SR, Gabow PA, Cramer J, et al.: The role of alcohol in new-onset atrial fibrillation. Arch Intern Med 1983. 143: 1882–1885.

    Article  PubMed  CAS  Google Scholar 

  11. Levy S: Factors predisposing to the development of atrial fibrillation. Pacing Clin Electrophysiol1997, 20(pt 2 ): 2670–2674.

    Google Scholar 

  12. Allessie MA: Is atrial fibrillation sometimes a genetic disease? editorial; comment. NEnglJMed 1997, 336: 950–952.

    Article  CAS  Google Scholar 

  13. Wijffels MC, Kirchhof CS, Dorland R, et al.: Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995, 92: 1954–1968.

    Article  PubMed  CAS  Google Scholar 

  14. Levy S: Classification system of atrial fibrillation. Curr Opin Cardiol 2000, 15: 54–57.

    Article  PubMed  CAS  Google Scholar 

  15. Wijffels MC: The natural history of atrial fibrillation: what is the role of atrial remodeling and what can we learn from the atrial defibrillator? editorial; comment. J Cardiovasc Electrophysiol 1999, 10: 1210–1213.

    Article  PubMed  CAS  Google Scholar 

  16. Van Gelder IC, Crijns HJ, VanGilst WH, et al.: Decrease of right and left atrial sizes after direct-current electrical cardioversion in chronic atrial fibrillation. Am J Cardiol1991, 67: 93–95.

    Google Scholar 

  17. Seto TB, Taira DA, Manning WJ: Cardioversion in patients with atrial fibrillation and left atrial thrombi on initial trans-esophageal echocardiography: should transesophageal echocardiography be repeated before elective cardioversion? A cost-effectiveness analysis see comments. JAm Soc Echocardiogr 1999, 12: 508–516.

    Article  CAS  Google Scholar 

  18. Silverman DI, Manning WJ: Role of echocardiography in patients undergoing elective cardioversion of atrial fibrillation see comments. Circulation 1998, 98: 479–486.

    Article  PubMed  CAS  Google Scholar 

  19. Klein AL, Grim RA, Black IW, et al.: Cardioversion guided by transesophageal echocardiography: the ACUTE Pilot Study. A randomized, controlled trial. Assessment of Cardioversion Using Transesophageal Echocardiography see comments. Ann Intern Med 1997, 126: 200–209.

    PubMed  CAS  Google Scholar 

  20. Prystowsky EN: Management of atrial fibrillation: therapeutic options and clinical decisions. Am J Cardio12000, 85(suppl 1 ): 3–11.

    Google Scholar 

  21. Reiter M, Reiffel J, Kowey P, et al.: Therapeutic Options for Atrial Fibrillation: Treatment Strategies for a New Millennium. CVRR. 2000, 121: 302–323.

    Google Scholar 

  22. Stafford RS, Robson DC, Misra B et al.: Rate control and sinus rhythm maintenance in atrial fibrillation: national trends in medication use, 1980–1996, Arch Intern Med 1998, 158: 2144–2148.

    Article  PubMed  CAS  Google Scholar 

  23. McAlister FA, Ackman ML, Tsuyuki RT, et al.: Contemporary utilization of digoxin in patients with atrial fibrillation. Clinical Quality Improvement Network Investigators. Ann Pharmacother 1999, 33: 289–293.

    Article  PubMed  CAS  Google Scholar 

  24. Falk RH: Pharmacologic control of heart rate in atrial fibrillation. Cardiol Clin 1996, 14: 521–536.

    PubMed  CAS  Google Scholar 

  25. Kay GN, Ellenbogen KA, Guidici M, et al.: The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators see comments. Jlntery Card Electrophysiol1998, 2: 121–135.

    Google Scholar 

  26. Phillips BG, Bauman JL: Prescribing trends and pharmacoeconomic considerations in the treatment of arrhythmias: focus on atrial fibrillation and flutter. Pharmacoeconomics 1995, 7: 521–533.

    Article  PubMed  CAS  Google Scholar 

  27. Paquette M, Roy D, Talajic M, et al.: Sinus rhythm at the time of assessment is associated with better quality of life than AF or flutter: results from the Canadian Trial of Atrial Fibrillation. PACE 1999, 22: 863.

    Google Scholar 

  28. Coplen SE, Antman EM, Berlin JA, et al.: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials published erratum appears in Circulation 1991, 83:714; see comments. Circulation 1990, 82: 1106–1116.

    CAS  Google Scholar 

  29. Flaker GC, Blackshear JL, McBride R, et al.: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Investigators. JAm Coll Cardiol 1992, 20: 527–532.

    Article  CAS  Google Scholar 

  30. Atrial fibrillation follow-up investigation of rhythm management: the AFFIRM study design: The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators. Am J Cardiol1997, 79:1198–1202.

    Google Scholar 

  31. Duytschaever M, Haerynck F, Tavernier R, et al.: Factors influencing long term persistence of sinus rhythm after a first electrical cardioversion for atrial fibrillation. Pacing Clin Electrophysiol 1998, 21 (pt 2): 284–287.

    Article  PubMed  CAS  Google Scholar 

  32. Verhorst PM, Kamp O, Welling RC, et al.: Transesophageal echocardiographic predictors for maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation. Am J Cardiol 1997, 79: 1355–1359.

    Article  PubMed  CAS  Google Scholar 

  33. Kerber RE: Transthoracic cardioversion of atrial fibrillation and flutter: standard techniques and new advances. Am J Cardiol1996, 78(suppl A):22–26.

    Google Scholar 

  34. Levy S: Cardioversion of chronic atrial fibrillation-towards a more aggressive approach editorial; comment. EurHeartJ2000, 21: 263.

    Google Scholar 

  35. Roy D, Talajic M, Dorian P, et al.: Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. NEnglJMed 2000, 342: 913–920.

    Article  CAS  Google Scholar 

  36. Vitolo E, Tronci M, Larovere MT, et al.: Amiodarone versus quinidine in the prophylaxis of atrial fibrilation. Acta Cardiologica 1981, 36: 431–434.

    PubMed  CAS  Google Scholar 

  37. Zarembski DG, Nolan PE Jr, Slack MK, et al.: Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide. Arch Intern Med 1995, 155: 1885–1891.

    Article  PubMed  CAS  Google Scholar 

  38. Kochiadakis GE, Igoumenidis NE, Marketou ME,et al.: Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardil1998, 81: 995–998.

    Google Scholar 

  39. Kochiadakis GE, Igoumenidis NE, Marketou ME, et al.: Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. JAm Coll Cardiol 1999, 33: 966–971.

    Article  CAS  Google Scholar 

  40. Chun SH, Sager PT, Stevenson WG, et al.: Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter see comments. Am J Cardiol 1995, 76: 47–50.

    Article  PubMed  CAS  Google Scholar 

  41. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med 1987, 147: 1561–1564.

    Article  PubMed  CAS  Google Scholar 

  42. Wolf PA, D’Agostino RB, Belanger AG, et al.: Probability of stroke: a risk profile from the Framingham Study. Stroke 1991, 22: 312–318.

    Article  PubMed  CAS  Google Scholar 

  43. Wolf PA, D’Agostino RB, Belanger AG, et al.: Secular trends in the prevalence of atrial fibrillation: the Framingham Study. Am HeartJ1996, 131: 790–795.

    Google Scholar 

  44. Wolf PA, Singer DE: Preventing stroke in atrial fibrillation. Am Fam Physician 1997, 56: 2242–2250.

    PubMed  CAS  Google Scholar 

  45. Wolf PA: Prevention of stroke. Lancet 1998, 352 (suppl): 15–18.

    Article  Google Scholar 

  46. Albers GW: Choice of antithrombotic therapy for stroke prevention in atrial fibrillation: warfarin, aspirin, or both? editorial; comment Arch Intern Med 1998, 158: 1487–1491.

    PubMed  CAS  Google Scholar 

  47. Kottkamp H Hindricks G, Breithardt G: Role of anticoagulant therapy in atrial fibrillation. J Cardiovasc Electrophysiol 1998, 9 (suppl): 86–96.

    Google Scholar 

  48. Morley J, Marinchak R, Rials SJ, et al.: Atrial fibrillation, anticoagulation, and stroke. Am J Cardiol1996, 77(suppl):38–44.

    Google Scholar 

  49. Nademanee K, Kosar EM: Long-term antithrombotic treatment for atrial fibrillation. Am J Cardiol1998, 82(suppl A):37–42.

    Google Scholar 

  50. Albers GW, Sherman DG, Gress DR, et al.: Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. Ann Neurol1991, 30: 511–518.

    Google Scholar 

  51. Albers GW: Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med 1994, 154: 1443–1448.

    Article  PubMed  CAS  Google Scholar 

  52. Mendelson G, Aronow WS: Underutilization of warfarin in older persons with chronic nonvalvular atrial fibrillation at high risk for developing stroke see comments. JAm Geriatr Soc 1998, 46: 1423–1424.

    CAS  Google Scholar 

  53. Stafford RS, Singer DE: Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998, 97: 1231–1233.

    Article  PubMed  CAS  Google Scholar 

  54. Raker GC, McGowan DJ, Bocchler M, et al.: Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation. Am Heart J 1999, 137: 307–312.

    Article  Google Scholar 

  55. Smith NL, Psaty BM, Furberg CD, et al.: Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. Arch Intern Med 1999, 159: 1574–1548.

    Article  PubMed  CAS  Google Scholar 

  56. Thibault B, Nattel S: Optimal management with Class I and Class III antiarrhythmic drugs should be done in the outpatient setting: protagonist. J Cardiovasc Electrophysiol1999, 10: 472–481.

    Google Scholar 

  57. Simons GR, Eisenstein EL, Shaw LJ, et al.: Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias. Am J Cardiol1997, 80: 1551–1557.

    Google Scholar 

  58. Capucci A, Villani GO, Piepoli MF, et al.: The role of oral 1C antiarrhythmic drugs in terminating atrial fibrillation. Curr Opin Cardiol1999, 14: 4–8.

    Google Scholar 

  59. Weinfeld MS, Drazner MH, Stevenson WG, et al.: Early outcome of initiating amiodarone for atrial fibrillation in advanced heart failure. J Heart Lung Transplant 2000, 19: 638–643.

    Article  PubMed  CAS  Google Scholar 

  60. Olshansky, B: Management of atrial fibrillation after coronary artery bypass graft. Am J Cardiol1996, 78(suppl A):27–34.

    Google Scholar 

  61. Mead GE, et al.: Cardioversion for atrial fibrillation: the views of consultant physicians, geriatricians and cardiologists. Age Aging 1999, 28: 73–75.

    Article  CAS  Google Scholar 

  62. Cannom DS: Atrial fibrillation: nonpharmacologic approaches. Am J Cardio12000, 85(suppl):25–35.

    Google Scholar 

  63. Hohnloser SH, Li YG, Bender B, et al.: Pharmacological management of atrial fibrillation: an update. J Cardiovasc Pharmacol Ther 2000, 5: 11–16.

    Article  PubMed  CAS  Google Scholar 

  64. McClellan KJ, Markham A: Dofetilide: a review of its use in atrial fibrillation and atrial flutter. Drugs 1999, 58: 1043–1059.

    Article  PubMed  CAS  Google Scholar 

  65. Karam R, Marcello S, Brooks RR, et al.: Azimilide dihydrochloride, a novel antiarrhythmic agent. Am J Cardiol 1998, 81 (suppl A): 40–46.

    Article  Google Scholar 

  66. Sager PT: New advances in class III antiarrhythmic drug therapy. Curr Opin Cardiol2000, 15: 41–53.

    Google Scholar 

  67. Baerman JM, Olshansky B, Wilber DJ: Advances in the nonpharmacologic treatment of atrial fibrillation. Jlnvasive Cardiol 1992, 4: 160–166.

    CAS  Google Scholar 

  68. Cannom DS: Atrial fibrillation: nonpharmacologic approaches. Am J Cardiol2000, 85(suppl A):25–35.

    Google Scholar 

  69. Keane D, Zou L, Ruskin J: Nonpharmacologic therapies for atrial fibrillation. Am J Cardiol1998, 81(suppl A):41–45.

    Google Scholar 

  70. Murgatroyd FD, Leenhardt A: Non-pharmacological treatments for atrial fibrillation: a critical perspective on the status quo. Arch Mal Coeur Vaiss 2000, 93: 7–16.

    PubMed  CAS  Google Scholar 

  71. Saksena S: Pacing therapy for atrial fibrillation. Thorac Cardiovasc Surg 1999, 47 (suppl): 339–341.

    Article  PubMed  Google Scholar 

  72. Connolly SJ, Kerr CR, Gent M, et al.: Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. NEnglJMed 2000 342: 1385–1391.

    Article  CAS  Google Scholar 

  73. Jais P, Haissaguerre M, Shah DC, et al.: A focal source of atrial fibrillation treated by discrete radiofrequency ablation see comments. Circulation 1997, 95: 572–576.

    Article  PubMed  CAS  Google Scholar 

  74. Jais P, Shah DC, Takahashi A, et al.: Long-term follow-up after right atrial radiofrequency catheter treatment of paroxysmal atrial fibrillation. Pacing Clin Electrophysio11998, 21: 2533–2538.

    Google Scholar 

  75. Jais P, Shah DC, Haissaguerre M, et al.: Catheter ablation for atrial fibrillation. Annu Rev Med 2000, 51: 431–441.

    Article  PubMed  CAS  Google Scholar 

  76. Jais P, Shah DC, Haissaguerre M, et al.: Atrial fibrillation: role of arrhythmogenic foci. Jlntery Card Electrophysiol2000, 4 Suppl 1: 29–37.

    Google Scholar 

  77. Ayers GM: New concepts in atrial defibrillation. Jlntery Card Electrophysiol2000, 4(suppl):155–161.

    Google Scholar 

  78. Chen L, Keane AT, Every NR: The Food and Drug Administration and atrial defibrillation devices. Am JManag Care 1999, 5: 899–909.

    CAS  Google Scholar 

  79. Griffin JC: Indications for an atrial defibrillator. J Cardiovasc Electrophysiol1998, 9(suppl):187–192.

    Google Scholar 

  80. Heisel A, Jung J: The atrial defibrillator: a stand-alone device or part of a combined dual-chamber system? Am J Cardiol 1999, 83: 218–226.

    Article  Google Scholar 

  81. Josephson ME: New approaches to the management of atrial fibrillation: the role of the atrial defibrillator editorial. Circulation 1998, 98: 1594–1596.

    Article  PubMed  CAS  Google Scholar 

  82. Cox JL, Ad N, Palazzo T, et al.: Current status of the Maze procedure for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg 2000, 12: 15–19.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Hongsheng M. Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Omer A. Bajwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brian Olshansky
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, University of Arizona, Health Sciences Center, Tucson, Arizona, USA

    Joseph S. Alpert MD (Professor and Chairman, Professor of Medicine, Head) (Professor and Chairman, Professor of Medicine, Head)

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Current Medicine, Inc.

About this chapter

Cite this chapter

Guo, H.M., Bajwa, O.A., Olshansky, B. (2001). Atrial Fibrillation: Practical Approaches. In: Alpert, J.S. (eds) Cardiology for the primary care Physician. Current Medicine Group. https://doi.org/10.1007/978-1-4615-6601-4_46

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-6601-4_46

  • Publisher Name: Current Medicine Group

  • Print ISBN: 978-1-4615-6603-8

  • Online ISBN: 978-1-4615-6601-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation